AngioLab (XKRX:251280) Research & Development : ₩1,098.5 Mil (TTM As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is AngioLab Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. AngioLab's Research & Development for the six months ended in Dec. 2023 was ₩1,098.5 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 was ₩1,098.5 Mil.

AngioLab Research & Development Historical Data

The historical data trend for AngioLab's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AngioLab Research & Development Chart

AngioLab Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Research & Development

Get a 7-Day Free Trial

2,444.65

2,946.23

1,503.51

1,537.96

1,098.48

AngioLab Semi-Annual Data
	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
Research & Development	Get a 7-Day Free Trial			2,444.65	2,946.23	1,503.51	1,537.96	1,098.48

AngioLab Research & Development Calculation

This is the expense the company spent on research and development.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 was ₩1,098.5 Mil.

AngioLab (XKRX:251280) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

AngioLab Research & Development Related Terms

Thank you for viewing the detailed overview of AngioLab's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

AngioLab (XKRX:251280) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AngioLab Inc (XKRX:251280) » Definitions » Research & Development

Comparable Companies

Traded in Other Exchanges

N/A

Address

65 Techno 3ro, Suite 159, Hanshin S Mecca, Yuseong-gu, Doejeon, CHN

Website

http://www.angiolab.co.kr

AngioLab Inc is a biotechnology company. It develops products based on angiogenesis inhibitors. It discovers, develops, and markets anti-angiogenic candidates to inhibit the abnormal growth of new blood vessel.

AngioLab (XKRX:251280) Headlines

No Headlines